Nkarta announces positive preliminary dose finding data for two lead engineered natural killer cell programs

Nkx101 – 3 of 5 patients with relapsed / refractory aml treated with a three-dose regimen consisting of 1b or 1.5b car nk cells per dose achieved complete response with full hematologic recovery (60% cr rate); 2 of 3 crs are mrd negative
NKTX Ratings Summary
NKTX Quant Ranking